Affiliations: [a] Department of Hematology, Trabzon Kanuni Training and Research Hospital, Trabzon, Turkey | [b] Department of Hematology, School of Medicine, Karadeniz Technical University, Trabzon, Turkey | [c] Department of Medical Biochemistry, School of Medicine, Karadeniz Technical University, Trabzon, Turkey | [d] Department of Public Health, School of Medicine, Karadeniz Technical University, Trabzon, Turkey
Correspondence:
[*]
Corresponding author: Nergiz Erkut, Department of Hematology, Trabzon Kanuni Training and Research Hospital, Trabzon, Turkey. Tel.: +90 462 3415656; Fax: +90 462 3447777; E-mail:drnusta@hotmail.com
Abstract:
BACKGROUND: Hypoxia plays an important role in the development and
progression of hematologic malignancies. OBJECTIVE: This study was intended to investigate the effectiveness
of ischemia-modified albumin (IMA) for demonstrating hypoxia in patients
with acute leukemia. METHODS: Blood specimens were collected from 132 subjects (44 acute
leukemia patients, 40 iron deficiency anemia (IDA) patients and 48 healthy
controls). Serum levels of IMA and malondialdehyde (MDA) were analyzed using
conventional methods. RESULTS: Serum levels of IMA were higher in patients with acute
leukemia than in those with IDA and healthy controls (acute leukemia
patients; 0.69 ± 0.14 ABSUs, IDA patients; 0.61 ± 0.09 ABSUs,
controls; 0.50 ± 0.09 ABSUs, respectively). There was a negative
correlation between serum IMA levels and hemoglobin (Hb) values (r = - 0.312)
and between serum IMA levels and hematocrit (Hct) values, (r = - 0.305) in patients
with acute leukemia. Serum levels of MDA were higher in
patients with acute leukemia than in those with IDA. But there was no
difference in patients with acute leukemia and IDA compared to healthy
controls (acute leukemia patients; 2.23 ± 1.82 nmol/mL, IDA patients;
1.36 ± 0.94 nmol/mL, healthy controls; 1.79 ± 0.78 nmol/mL, respectively). CONCLUSIONS: IMA can be effective for demonstrating hypoxia in
patients with acute leukemia.
